BR0111868A - Composições farmacêuticas - Google Patents

Composições farmacêuticas

Info

Publication number
BR0111868A
BR0111868A BR0111868-4A BR0111868A BR0111868A BR 0111868 A BR0111868 A BR 0111868A BR 0111868 A BR0111868 A BR 0111868A BR 0111868 A BR0111868 A BR 0111868A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
valsartan
compositions
bioavailable
hydrate
Prior art date
Application number
BR0111868-4A
Other languages
English (en)
Portuguese (pt)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0111868A publication Critical patent/BR0111868A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0111868-4A 2000-06-22 2001-06-20 Composições farmacêuticas BR0111868A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59968700A 2000-06-22 2000-06-22
PCT/EP2001/006983 WO2001097805A2 (en) 2000-06-22 2001-06-20 Solid valsartan pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR0111868A true BR0111868A (pt) 2003-07-01

Family

ID=24400655

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111868-4A BR0111868A (pt) 2000-06-22 2001-06-20 Composições farmacêuticas

Country Status (21)

Country Link
EP (2) EP1296677A2 (enExample)
JP (3) JP2003535895A (enExample)
KR (2) KR100659644B1 (enExample)
CN (2) CN100450478C (enExample)
AU (2) AU8576801A (enExample)
BR (1) BR0111868A (enExample)
CA (1) CA2411882C (enExample)
CZ (1) CZ20024180A3 (enExample)
EC (1) ECSP024389A (enExample)
HK (1) HK1052868A1 (enExample)
HU (1) HUP0301390A3 (enExample)
IL (2) IL153428A0 (enExample)
MX (1) MXPA02012683A (enExample)
NO (1) NO20026123L (enExample)
NZ (2) NZ540748A (enExample)
PL (1) PL358290A1 (enExample)
RU (1) RU2333757C2 (enExample)
SG (1) SG162605A1 (enExample)
SK (1) SK18062002A3 (enExample)
WO (1) WO2001097805A2 (enExample)
ZA (1) ZA200210359B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE354364T1 (de) * 1998-12-23 2007-03-15 Novartis Pharma Gmbh Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind
PL212318B1 (pl) * 2002-01-17 2012-09-28 Novartis Ag Kompozycja farmaceutyczna zawierajaca walsartan oraz inhibitor obojetnej endopeptydazy (NEP) oraz zestaw zawierajacy te kompozycje
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
KR20080083071A (ko) 2003-08-08 2008-09-12 아지노모토 가부시키가이샤 나테글리니드 함유 제제
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
CA2592091A1 (en) 2004-12-24 2006-06-29 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
JP2009001520A (ja) * 2007-06-21 2009-01-08 Kowa Co ジフェンヒドラミン含有固形製剤
RU2487710C2 (ru) 2007-10-09 2013-07-20 Новартис Аг Фармацевтическая композиция валсартана
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
SI2536396T1 (sl) 2010-02-16 2017-01-31 KRKA, tovarna zdravil, d.d.,Novo mesto Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
CN102362865B (zh) * 2011-10-28 2013-06-26 山东司邦得制药有限公司 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
CN103599084B (zh) * 2013-11-22 2018-10-30 威海迪素制药有限公司 一种降压组合物
CN112807286A (zh) * 2021-01-20 2021-05-18 海南皇隆制药股份有限公司 一种缬沙坦分散片制备方法和缬沙坦分散片
CN112826806A (zh) * 2021-01-20 2021-05-25 海南皇隆制药股份有限公司 一种缬沙坦片制备方法和缬沙坦片
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000024I1 (de) 1990-02-19 2010-07-08 Novartis Ag Acylverbindungen
BR9507086A (pt) * 1994-03-17 1997-09-16 Ciba Geigy Ag Tratamento de nefroterapia diabética com valsartan
ES2167571T3 (es) * 1995-06-07 2002-05-16 Searle & Co Terapia de combinacion de antagonista de aldosterona epoxi-esteroideo y antagonista de angiotensina ii para el tratamiento del fallo cardiaco congestivo.
PT853477E (pt) * 1995-10-06 2003-01-31 Novartis Ag Antagonistas de receptores at1 para prevencao e tratamento de insuficiencia renal pos-isquemica e para proteccao de rim isquemico
ES2189940T3 (es) * 1996-02-29 2003-07-16 Novartis Ag Antagonista de receptor at1 para la estimulacion de la apoptosis.
CN1165291C (zh) * 1996-05-20 2004-09-08 詹森药业有限公司 具有改进的生物利用度的抗真菌组合物
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
ATE354364T1 (de) * 1998-12-23 2007-03-15 Novartis Pharma Gmbh Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind
PE20020229A1 (es) * 2000-04-12 2002-04-11 Novartis Ag COMBINACION DE UN ANTAGONISTA DEL RECEPTOR AT1; UN INHBIDOR DE HMG-CoA REDUCTASA Y UN INHIBIDOR DE ACE

Also Published As

Publication number Publication date
HK1052868A1 (zh) 2003-10-03
KR20030019450A (ko) 2003-03-06
CA2411882C (en) 2011-09-06
KR100659644B1 (ko) 2006-12-21
CN1221256C (zh) 2005-10-05
IL153428A0 (en) 2003-07-06
NO20026123L (no) 2003-02-18
KR20050085978A (ko) 2005-08-29
KR100525341B1 (ko) 2005-11-02
HUP0301390A3 (en) 2005-04-28
MXPA02012683A (es) 2003-04-25
IL153428A (en) 2013-12-31
CZ20024180A3 (cs) 2003-04-16
JP2012211200A (ja) 2012-11-01
CA2411882A1 (en) 2001-12-27
AU8576801A (en) 2002-01-02
JP2003535895A (ja) 2003-12-02
NO20026123D0 (no) 2002-12-19
CN1679551A (zh) 2005-10-12
EP2072049A2 (en) 2009-06-24
EP2072049A3 (en) 2009-12-30
HK1083452A1 (zh) 2006-07-07
HUP0301390A2 (hu) 2003-11-28
ECSP024389A (es) 2003-02-06
RU2333757C2 (ru) 2008-09-20
ZA200210359B (en) 2003-11-13
JP2007091758A (ja) 2007-04-12
WO2001097805A3 (en) 2002-08-29
EP1296677A2 (en) 2003-04-02
CN100450478C (zh) 2009-01-14
SK18062002A3 (sk) 2003-07-01
WO2001097805A2 (en) 2001-12-27
NZ522953A (en) 2005-10-28
NZ540748A (en) 2007-04-27
PL358290A1 (en) 2004-08-09
SG162605A1 (en) 2010-07-29
CN1437469A (zh) 2003-08-20
AU2001285768B2 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
BR0111868A (pt) Composições farmacêuticas
BR0015188A (pt) Composições farmacêuticas
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
EA200400471A1 (ru) Оральная дозированная форма пропиверина
YU58103A (sh) Farmaceutski preparati, dozirane forme i postupci za oralnu primenu epotilona
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
FI973518A7 (fi) Piperidinoalkanoliyhdistettä tai sen farmaseuttisesti hyväksyttävää suolaa sisltävä farmaseuttinen koostumus kiinteässä yksikköannosmuodossa
EP1246622A4 (en) NEW SUBSTITUTED DOSE FORMS OF BENZIMIDAZOLENES AND METHOD FOR THE USE THEREOF
NO20043367L (no) Oralt farmasoytisk preparat
BR0209489A (pt) Composições farmacêuticas
DE69413237D1 (en) Plättchenaggregationsinhibitoren
WO2002094774A3 (en) Oxcarbazepine dosage forms
GEP20063882B (en) Dosage regimen and pharmaceutical composition for emergency contraception
DE122006000057I2 (de) Proteinhaltige arzneimittel
PL348419A1 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
WO2005004915A3 (en) Compositions comprising meloxicam
DE69530123D1 (en) Plättchenaggregationsinhibitoren
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
GEP20043377B (en) Pharmaceutical Complex
BR0213463A (pt) Composições farmacêuticas contendo macrólidos
DK1399141T3 (da) Anvendelse af acetyl L-carnitin til fremstilling af et lægemiddel til forebyggende terapi af post-kirurgisk smerte
YU59102A (sh) JEDINJENJA KORISNA ZA LEČENJE ILI PREVENCIJU OBOLJENJA U KOJEM UČESTVUJE ALFA-2β-ADRENOCEPTOR

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]